CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

SeedInvest

Tai Nicolopoulos, Head of Marketing

Startups In The Coronavirus Era: The Acceleration Of Online Fundraising

Tai Nicolopoulos

Tai Nicolopoulos

Over the past decade, there has been an accelerating, long-term shift in most types of commerce and consumption moving online, and COVID-19 seems to be a catalyst to accelerating this shift. At SeedInvest, an equity crowdfunding platform which has successfully funded over 200 companies since its inception, we polled founders to gain a deeper understanding of how startups are responding to COVID-19, and how the economic climate resulting from this crisis has impacted their plans to deploy and raise capital.


Our main takeaway is that COVID-19 has slowed, but not stopped fundraising efforts, and has led founders to consider more alternatives to traditional venture capital. Below are highlights from the results of this survey.


Who are our respondents?


● Out of the 70 startup founders who participated, 28% are international, 22% are based on the West Coast, 15% are based on the East Coast, another 15% are based in the South, and the remainder are spread across the Midwest.


● The companies also fall across a wide range of industries, with the top represented sectors being: healthcare (19%), technology (19%), B2B SaaS (10%), and Entertainment (8%).


● The participating companies range from pre-seed to Series C, with a median $5.7 mm in total capital raised.


The majority of respondents are either raising capital or will be soon.


● 36% of respondents are currently fundraising, an additional 22% are looking to raise in the next three months, and a further, 18% are looking to raise in the next six months.


COVID-19 is causing founders to consider alternative sources of funding:


● 60% of founders said they were more likely to raise from a new investor or investors with whom they had not worked previously.


● 44% of founders said that COVID-19 made them more likely to consider online equity crowdfunding platforms for their next raise, vs. 52% who were no more or less likely to consider it, and 4% who said they were less likely to consider it.


Fundraising is happening remotely, but a personal connection with investors still matters.


● The three most popular tools with participating founders were personal emails, phone calls, and Video Conferencing, with founders stating their experiences fundraising with these tools had been, on average, “Quite Positive” (8 out of 10). Meanwhile, their experiences with “cold” or mass emails, webinars, syndicates, and unsolicited outreach via LinkedIn had been “Quite Negative” (2 out of 10) on average.


"Our main takeaway is that COVID-19 has slowed, but not stopped fundraising efforts, and has led founders to consider more alternatives to traditional venture capital"


Investment is still occurring, albeit a little more slowly.


● 48% of founders said that investors were just as responsive as before. Meanwhile, 37% said they were less responsive, and just 15% said investors were more responsive.


● 44% of founders said they are delaying or previously delayed a raise because of COVID- 19, vs. 23% who are accelerating the timeline of an upcoming raise.


In the COVID-19 era, remote working is here to stay, as is remote investing. In fact, pitching to investors or finding a crowd funding platform to help fund your business may be easier and more accessible than ever. With offices closed, founders no longer need to physically travel to tech hubs such as Silicon Valley to pitch their business idea. This larger secular shift that is moving traditional startup fundraising and investing online could be the new normal.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://biotech-startups.lifesciencesreview.com/leadership-perspective/startups-in-the-coronavirus-era-the-acceleration-of-online-fundraising-nwid-419.html